BAKER BROS. ADVISORS LP
Q2 2023 13F-HR Holdings
Net value change ($000)
-1,100,508
(-6.0%)
New positions
9
Sold out positions
8
Turnover %
0.7%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q1 2023
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| ACAD | 237,325 | 30.1% |
| ROIV | 59,783 | 169.6% |
| IMTX | 29,304 | 81.9% |
| ImmunoGen, Inc. | 28,684 | NEW |
| ABCL | 27,474 | 34.9% |
| IMCR | 26,518 | 21.3% |
| REPL | 25,456 | 31.5% |
| CHINOOK THERAPEUTICS, INC. | 22,221 | 66.0% |
| AKRO | 19,966 | 22.0% |
| DICE Therapeutics, Inc. | 18,448 | 62.2% |
Top Reduces (Value $000, Stocks/ETFs)
| Seagen Inc. | -923,737 | -9.7% |
| ONC | -434,433 | -17.3% |
| INCY | -362,312 | -13.9% |
| KYNB | -48,571 | -98.7% |
| BMRN | -40,237 | -10.9% |
| BMEA | -19,108 | -29.2% |
| MDGL | -17,398 | -4.6% |
| BCRX | -16,524 | -15.6% |
| BPMC | -15,012 | -100.0% |
| IGM Biosciences, Inc. | -14,231 | -32.8% |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|